Compare AACG & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AACG | NEPH |
|---|---|---|
| Founded | 1999 | 1997 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.5M | 49.4M |
| IPO Year | 2008 | 2004 |
| Metric | AACG | NEPH |
|---|---|---|
| Price | $0.82 | $3.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 4.6K | ★ 18.3K |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1000.00 |
| EPS | N/A | ★ 0.12 |
| Revenue | N/A | ★ $18,789,000.00 |
| Revenue This Year | N/A | $17.81 |
| Revenue Next Year | N/A | $15.90 |
| P/E Ratio | ★ N/A | $32.42 |
| Revenue Growth | N/A | ★ 32.67 |
| 52 Week Low | $0.74 | $2.66 |
| 52 Week High | $1.50 | $6.42 |
| Indicator | AACG | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 37.63 |
| Support Level | N/A | $3.19 |
| Resistance Level | N/A | $3.78 |
| Average True Range (ATR) | 0.00 | 0.23 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 0.00 | 0.00 |
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments of the company are (i) Overseas art study services (ii) Other educational services and (iii) Other services. Majority of its revenue comes from Overseas art study services.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.